- Home
- MBIN vs TNGX Comparison
MBIN vs TNGX Comparison
Compare MBIN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBIN | TNGX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBIN | TNGX |
|---|---|---|
| Price | $41.76 | $17.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $43.67 | $18.75 |
| AVG Volume (30 Days) | 241.4K | ★ 3.4M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,384,000.00 |
| Revenue This Year | $31.76 | N/A |
| Revenue Next Year | $3.73 | $13.81 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $27.25 | $1.04 |
| 52 Week High | $48.50 | $17.63 |
Technical Indicators
Market Signals| Indicator | MBIN | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 72.25 |
| Support Level | $30.89 | $10.90 |
| Resistance Level | $48.50 | $17.63 |
| Average True Range (ATR) | 1.38 | 1.15 |
| MACD | -0.44 | 0.45 |
| Stochastic Oscillator | 37.71 | 95.02 |
Price Performance
Historical ComparisonAbout MBIN Merchants Bancorp
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.